Skip to main content

Liminal BioSciences Inc. (LMNL)

NASDAQ: LMNL · IEX Real-Time Price · USD
2.55
+0.05 (2.00%)
After-hours:Sep 24, 2021 6:12 PM EDT
2.50
-0.08 (-3.10%)
At close: Sep 24, 4:00 PM
Market Cap74.86M
Revenue (ttm)1.54M
Net Income (ttm)-94.68M
Shares Out29.94M
EPS (ttm)-3.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume80,460
Open2.55
Previous Close2.58
Day's Range2.47 - 2.60
52-Week Range2.13 - 11.99
Beta1.41
AnalystsBuy
Price Target13.29 (+431.4%)
Est. Earnings DateNov 11, 2021

About LMNL

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of i...

IndustryBiotechnology
CEOKenneth Galbraith
Employees251
Stock ExchangeNASDAQ
Ticker SymbolLMNL
Full Company Profile

Financial Performance

In 2020, LMNL's revenue was 3.32 million, a decrease of -32.36% compared to the previous year's 4.90 million. Losses were -119.59 million, -42.45% less than in 2019.

Financial numbers in millions CADFinancial Statements

Analyst Forecast

According to 2 analysts, the average rating for LMNL stock is "Buy." The 12-month stock price forecast is 13.29, which is an increase of 431.42% from the latest price.

Price Target
$13.29
(431.42% upside)
Analyst Consensus: Buy

News

After Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)

Liminal BioSciences Inc. (LMNL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni...

1 month ago - Zacks Investment Research

Liminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates

Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of 22.73% and -90.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Liminal BioSciences Reports Second Quarter 2021 Financial Results

Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedri...

1 month ago - PRNewsWire

Liminal BioSciences Stock Is Trading Higher On Sale Of Priority Review Voucher For $105M

Liminal BioSciences Inc's (NASDAQ: LMNL) subsidiary Prometic Biotherapeutics Inc has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105M. The FDA granted the PRV with the a...

1 month ago - Benzinga

Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeu...

1 month ago - PRNewsWire

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced toda...

2 months ago - PRNewsWire

Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business w...

LAVAL, QC and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, Kedrion S.p.A ("Kedrion") has exerc...

3 months ago - PRNewsWire

Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)

LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General and Sp...

3 months ago - PRNewsWire

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that the U.S. Food & Drug Administration (F...

3 months ago - PRNewsWire

Liminal BioSciences Stock Falls on Scrapping Further Development of Fezagepras

Based on interim pharmacokinetics (PK) results from the ongoing multiple ascending dose study Liminal BioSciences Inc (NASDAQ: LMNL) has decided not to move fezagepras into a Phase 2 study in Idiopathic...

3 months ago - Benzinga

Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

LAVAL, QC and CAMBRIDGE, England, May 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced toda...

3 months ago - PRNewsWire

Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement wi...

LAVAL, QC and CAMBRIDGE, England, May 21, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced toda...

4 months ago - PRNewsWire

Liminal BioSciences Reports First Quarter 2021 Financial Results

Updated Business Strategy Focused on Small Molecule Therapeutics Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic...

4 months ago - PRNewsWire

Liminal BioSciences To Offload Plasma Collection and Plasma-Derived Therapeutics Business To Kedrion

Liminal BioSciences Inc (NASDAQ: LMNL) has agreed to sell its plasma collection and plasma-derived therapeutics business to Kedrion S.P.A. Under the Share Purchase Agreement, Liminal will enter into an ...

4 months ago - Benzinga

Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutic...

Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Liminal to receive up to 70% of net proceeds...

4 months ago - PRNewsWire

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Liminal BioSciences Inc. (LMNL) Reports Q4 Loss, Tops Revenue Estimates

Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of -8.77% and 52.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors & Executive Team US$30M in gross proceeds from a pr...

6 months ago - PRNewsWire

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Bet on Rising P/E With These 5 Top-Ranked Stocks

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:BJBLCMQFINVCNXVIVO
8 months ago - Zacks Investment Research

Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announ...

9 months ago - PRNewsWire

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q3 2020 Results - Earnings Call Transcript

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q3 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference

LAVAL, QC and CAMBRIDGE, England, Nov. 13, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced tha...

10 months ago - PRNewsWire

Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call

LAVAL, QC and CAMBRIDGE, England, Nov. 10, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announc...

10 months ago - PRNewsWire